Chemcrux Enterprises Q2 Net Profit Jumps 103% YoY to Rs 1.62 Crore

CHEMICALS
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Chemcrux Enterprises Q2 Net Profit Jumps 103% YoY to Rs 1.62 Crore

Chemcrux Enterprises reported a strong standalone performance for the quarter ended September 30, 2026, with revenue rising 28.5% YoY to Rs 23.84 crore and net profit surging 103% to Rs 1.62 crore. The company also disclosed the incorporation of a new Section 8 subsidiary, Chemcrux Foundation, and updated shareholders on its recent ESOP grant process.

Chemcrux Enterprises Q2 Results Reveal Strong Operational Growth

Standalone Revenue: Rs 23.84 Crore | Standalone Net Profit: Rs 1.62 Crore

Reader Takeaway: Robust operational efficiency drove profits higher, though investors must track how subsidiary consolidations impact future bottom-line figures.

What just happened

Chemcrux Enterprises Limited posted its financial results for the quarter and half-year ended September 30, 2026. The company reported a significant standalone profit of Rs 1.62 crore, marking a 103% increase compared to the same quarter last year. Revenue from operations also saw a healthy uptick of 28.5% YoY, reaching Rs 23.84 crore. On a consolidated basis, the profit stood at Rs 0.55 crore, up from Rs 0.21 crore in the corresponding quarter of the previous year.

Why this matters

The sharp rise in standalone profitability highlights improved operational efficiency and effective cost management. For shareholders, this signals that the core business is scaling well. The distinction between standalone and consolidated figures is crucial, as the latter accounts for the company’s expanding group structure, including its subsidiaries.

Corporate Developments

During the quarter, the company finalized the incorporation of 'Chemcrux Foundation' on July 17, 2026. As a Section 8 entity, this subsidiary is focused on corporate social responsibility and currently holds no material impact on the company's financial results. Furthermore, the company updated investors on an ESOP grant of 1,07,700 options issued in May 2026, noting that an independent valuation process is ongoing.

Risks to watch

Investors should monitor the consolidated financial health of the firm as it integrates its new subsidiary foundation. While management does not expect the current ESOP valuation process to trigger material financial adjustments, it remains a procedural point for future disclosure.

Context metrics

For the first half of FY27, the company recorded total revenue of Rs 45.78 crore, compared to Rs 35.30 crore in H1 FY26. Total profit after tax for the six-month period reached Rs 3.00 crore, compared to Rs 1.38 crore in the prior year period.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.